Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology [Yahoo! Finance]